OptiBiotix Health plc (AIM: OPTI), a life sciences company specialising in microbiome-based health products, announced on Wednesday that it has signed a distribution agreement with a well-known direct selling weight management company.
Under the deal, OptiBiotix will supply SlimBiome finished products under the distributor's branding, as well as a WellBiome product to be included in its portfolio. The distributor plans to launch first in its largest sales territory, followed by other European markets, with products available through both e-commerce and a long-established consultant network. An initial order is expected within three months, with the official launch anticipated in H1 2026.
The agreement highlights growing demand for functional ingredients that complement the surge of interest in anti-obesity drugs. OptiBiotix's products are positioned to add scientifically backed functionality to established weight management brands.
Founded in 2012, OptiBiotix develops microbiome modulators targeting obesity, cardiovascular health and diabetes. The company has signed over 20 agreements with international food and healthcare firms and continues to expand its consumer supplement portfolio.
Viatris' generic iron sucrose injection gains US FDA approval
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
US FDA approves Innovent's IND application for IBI3032 oral GLP-1R agonist
GEN and Sulfateq report positive Phase 1 data for SUL-238 in Alzheimer's
Philips launches ECG AI Marketplace to streamline cardiac diagnostics
AstraZeneca's Baxdrostat meets all endpoints in pivotal Phase III hypertension trial
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
EDX Medical and Spire Healthcare sign strategic diagnostic partnership agreement
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies